Immutep Ltd ADR (IMMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immutep Ltd ADR (IMMP) has a cash flow conversion efficiency ratio of -0.284x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.12 Million) by net assets ($98.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immutep Ltd ADR - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Immutep Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IMMP total liabilities for a breakdown of total debt and financial obligations.
Immutep Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Afarak Group Oyj
HE:AFAGR
|
0.001x |
|
CAG Group AB (publ)
ST:CAG
|
-0.019x |
|
Stealth Group Holdings Ltd
AU:SGI
|
0.037x |
|
Wrap Technologies Inc
NASDAQ:WRAP
|
-0.206x |
|
Atrium Real Estate Investment Trust
KLSE:5130
|
0.125x |
|
Nova Minerals Limited
NYSE MKT:NVA
|
0.066x |
|
Roo Hsing Co Ltd
TW:4414
|
0.060x |
|
MFEC PCL
BK:MFEC
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Immutep Ltd ADR (2008–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Ltd ADR from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Immutep Ltd ADR (IMMP) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $143.64 Million | $-62.05 Million | -0.432x | -135.12% |
| 2024-06-30 | $189.52 Million | $-34.82 Million | -0.184x | +30.12% |
| 2023-06-30 | $136.47 Million | $-35.88 Million | -0.263x | +18.17% |
| 2022-06-30 | $94.08 Million | $-30.23 Million | -0.321x | -33.47% |
| 2021-06-30 | $73.27 Million | $-17.64 Million | -0.241x | +26.04% |
| 2020-06-30 | $33.30 Million | $-10.84 Million | -0.326x | +48.07% |
| 2019-06-30 | $24.39 Million | $-15.29 Million | -0.627x | -170.19% |
| 2018-06-30 | $33.52 Million | $-7.78 Million | -0.232x | +27.64% |
| 2017-06-30 | $26.53 Million | $-8.51 Million | -0.321x | -0.12% |
| 2016-06-30 | $35.32 Million | $-11.31 Million | -0.320x | -1.53% |
| 2015-06-30 | $24.69 Million | $-7.79 Million | -0.315x | +49.92% |
| 2014-06-30 | $22.59 Million | $-14.23 Million | -0.630x | -14.85% |
| 2013-06-30 | $29.25 Million | $-16.04 Million | -0.548x | -6.56% |
| 2012-06-30 | $37.16 Million | $-19.12 Million | -0.515x | -190.62% |
| 2011-06-30 | $55.10 Million | $-9.76 Million | -0.177x | +54.00% |
| 2010-06-30 | $16.79 Million | $-6.46 Million | -0.385x | +62.96% |
| 2009-06-30 | $1.81 Million | $-1.88 Million | -1.039x | -76.06% |
| 2008-06-30 | $2.63 Million | $-1.55 Million | -0.590x | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more